CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Lamivudine

拉米夫定 杂质对照品Lamivudine Impurities

EP32 个杂质条目32 impurity entries

本页汇总 拉米夫定 的 32 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 32 impurity reference standards of Lamivudine with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 拉米夫定(Lamivudine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and validation of quality by design stability-indicating method for quantitative determination of lamivudine and its impurities
    Journal of pharmaceutical sciences · 2025 · de Carvalho Mendes T et al.  ·  PMID 40482819  ·  DOI
  2. 杂质研究Impurity studiesSimultaneous Quantification of Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate in Human Plasma by UPLC-MS/MS: Method Development and Validation
    Turkish journal of pharmaceutical sciences · 2025 · Kanjarla N, Katta B  ·  PMID 40746245  ·  DOI
  3. 杂质研究Impurity studiesThe Validation of a Simple, Robust, Stability-Indicating RP-HPLC Method for the Simultaneous Detection of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir Sodium in Bulk Material and Pharmaceutical Formulations
    International journal of analytical chemistry · 2022 · Omoteso OA et al.  ·  PMID 35154325  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSynthesis of (±)-Emtricitabine and (±)-Lamivudine by Chlorotrimethylsilane-Sodium Iodide-Promoted Vorbrüggen Glycosylation
    The Journal of organic chemistry · 2022 · Mear SJ et al.  ·  PMID 35030006  ·  DOI
  • 合成方法SynthesisA Continuous Flow Sulfuryl Chloride-Based Reaction-Synthesis of a Key Intermediate in a New Route toward Emtricitabine and Lamivudine
    Organic process research & development · 2020 · de Souza JM et al.  ·  PMID 33100813  ·  DOI

拉米夫定 —— 原料药与杂质对照品Lamivudine — drug substance & impurities

共 33 个条目(含原料药本体)33 items incl. the drug substance
Lamivudine structure
EP原料药 APIAPI
拉米夫定Lamivudine
Lamivudine
CAS No.134678-17-4
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 1 (Lamivudine EP Impurity A) structure
EPA
拉米夫定杂质1 (拉米夫定EP杂质A)Lamivudine Impurity 1 (Lamivudine EP Impurity A)
Lamivudine Impurity 1 (Lamivudine EP Impurity A)
CAS No.173602-25-0
Chemical FormulaC8H9N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 2 (Lamivudine EP Impurity B) (Mixture of Enantiomers) structure
EPB
拉米夫定杂质2 (拉米夫定EP杂质B) (对映异构体混合物)Lamivudine Impurity 2 (Lamivudine EP Impurity B) (Mixture of Enantiomers)
Lamivudine Impurity 2 (Lamivudine EP Impurity B) (Mixture of Enantiomers)
CAS No.131086-22-1
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 4(Lamivudine EP Impurity D) structure
EPD
拉米夫定杂质4(拉米夫定EP杂质D)Lamivudine Impurity 4(Lamivudine EP Impurity D)
Lamivudine Impurity 4(Lamivudine EP Impurity D)
CAS No.134680-32-3
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 7(Lamivudine EP Impurity G) structure
EPG
拉米夫定杂质7(拉米夫定EP杂质G)Lamivudine Impurity 7(Lamivudine EP Impurity G)
Lamivudine Impurity 7(Lamivudine EP Impurity G)
CAS No.160552-55-6
Chemical FormulaC8H11N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 8(Lamivudine EP Impurity H) structure
EPH
拉米夫定杂质8(拉米夫定EP杂质H)Lamivudine Impurity 8(Lamivudine EP Impurity H)
Lamivudine Impurity 8(Lamivudine EP Impurity H)
CAS No.160552-54-5
Chemical FormulaC8H11N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 9 (Lamivudine EP Impurity I) structure
EPI
拉米夫定杂质9 (拉米夫定EP杂质I)Lamivudine Impurity 9 (Lamivudine EP Impurity I)
Lamivudine Impurity 9 (Lamivudine EP Impurity I)
CAS No.145918-75-8
Chemical FormulaC8H11N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 10 (Lamivudine EP Impurity J) structure
EPJ
拉米夫定杂质10 (拉米夫定EP杂质J)Lamivudine Impurity 10 (Lamivudine EP Impurity J)
Lamivudine Impurity 10 (Lamivudine EP Impurity J)
CAS No.145986-07-8
Chemical FormulaC8H10N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 11(Lamivudine Sulfoxide) structure
11
拉米夫定杂质11(拉米夫定亚砜)Lamivudine Impurity 11(Lamivudine Sulfoxide)
Lamivudine Impurity 11(Lamivudine Sulfoxide)
CAS No.1235712-40-9
Chemical FormulaC8H11N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 12 structure
12
拉米夫定杂质12Lamivudine Impurity 12
Lamivudine Impurity 12
CAS No.136846-20-3
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 16 structure
16
拉米夫定杂质16Lamivudine Impurity 16
Lamivudine Impurity 16
CAS No.147126-80-5
Chemical FormulaC18H27N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 17 structure
17
拉米夫定杂质17Lamivudine Impurity 17
Lamivudine Impurity 17
CAS No.147126-62-3
Chemical FormulaC14H24O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 19 structure
19
拉米夫定杂质19Lamivudine Impurity 19
Lamivudine Impurity 19
CAS No.1020151-61-4
Chemical FormulaC14H23ClO3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 22 structure
22
拉米夫定杂质22Lamivudine Impurity 22
Lamivudine Impurity 22
CAS No.200396-19-6
Chemical FormulaC14H24O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 25 structure
25
拉米夫定杂质25Lamivudine Impurity 25
Lamivudine Impurity 25
CAS No.18037-10-0
Chemical FormulaC10H21N3OSi2
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 27 structure
27
拉米夫定杂质27Lamivudine Impurity 27
Lamivudine Impurity 27
CAS No.389128-28-3
Chemical FormulaC18H26N2O5S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 31 structure
31
拉米夫定杂质31Lamivudine Impurity 31
Lamivudine Impurity 31
CAS No.928827-74-1
Chemical FormulaC9H11N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 33 structure
33
拉米夫定杂质33Lamivudine Impurity 33
Lamivudine Impurity 33
CAS No.139757-68-9
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 34 structure
34
拉米夫定杂质34Lamivudine Impurity 34
Lamivudine Impurity 34
CAS No.2165593-53-1
Chemical FormulaC8H9N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 35 structure
35
拉米夫定杂质35Lamivudine Impurity 35
Lamivudine Impurity 35
CAS No.2166332-84-7
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 36 structure
36
拉米夫定杂质36Lamivudine Impurity 36
Lamivudine Impurity 36
CAS No.2166395-21-5
Chemical FormulaC8H11N3O3S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 37 structure
37
拉米夫定杂质37Lamivudine Impurity 37
Lamivudine Impurity 37
CAS No.149819-44-3
Chemical FormulaC8H10N2O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 38 structure
38
拉米夫定杂质38Lamivudine Impurity 38
Lamivudine Impurity 38
CAS No.1415466-24-8
Chemical FormulaC8H9N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 39 structure
39
拉米夫定杂质39Lamivudine Impurity 39
Lamivudine Impurity 39
CAS No.111969-64-3
Chemical FormulaC12H22O4
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 40 structure
40
拉米夫定杂质40Lamivudine Impurity 40
Lamivudine Impurity 40
CAS No.173829-09-9
Chemical FormulaC8H9N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 41 structure
41
拉米夫定杂质41Lamivudine Impurity 41
Lamivudine Impurity 41
CAS No.147126-72-5
Chemical FormulaC18H27N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 42 structure
42
拉米夫定杂质42Lamivudine Impurity 42
Lamivudine Impurity 42
CAS No.953806-67-2
Chemical FormulaC12H22O4
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 43 structure
43
拉米夫定杂质43Lamivudine Impurity 43
Lamivudine Impurity 43
CAS No.1402543-99-0
Chemical FormulaC12H22O4
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 44 structure
44
拉米夫定杂质44Lamivudine Impurity 44
Lamivudine Impurity 44
CAS No.1638744-50-9
Chemical FormulaC14H24O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 45 structure
45
拉米夫定杂质45Lamivudine Impurity 45
Lamivudine Impurity 45
CAS No.147027-10-9
Chemical FormulaC18H27N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 48 structure
48
拉米夫定杂质48Lamivudine Impurity 48
Lamivudine Impurity 48
CAS No.1822826-02-7
Chemical FormulaC8H9N3O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 51 structure
51
拉米夫定杂质51Lamivudine Impurity 51
Lamivudine Impurity 51
CAS No.1309459-32-2
Chemical FormulaC14H24O4S
Purity>95%询价On request
10mg25mg50mg100mg
Lamivudine Impurity 47-13C,15N2 structure
47-13C
拉米夫定杂质47-13C,15N2Lamivudine Impurity 47-13C,15N2
Lamivudine Impurity 47-13C,15N2
CAS No.1217746-03-6
Chemical FormulaC713CH11N15N2O3S
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

拉米夫定 —— 研究文献与合成路线Lamivudine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 拉米夫定 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Lamivudine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Stability behavior of antiretroviral drugs and their combinations. 7: Comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behavior by density functional theory
    Kurmi M, Singh S · Journal of pharmaceutical and biomedical analysis · 2017 · 被引 11cited 11
  2. A simple stability indicating RP-HPLC-DAD method for concurrent analysis of Tenofovir Disoproxil Fumarate, Doravirine and Lamivudine in pure blend and their combined film coated tablets
    Godela R, Gummadi S · Annales pharmaceutiques francaises · 2021 · 被引 2cited 2
  3. Development and validation of quality by design stability-indicating method for quantitative determination of lamivudine and its impurities
    de Carvalho Mendes T, de Almeida RAD, de Mendonça Sousa FF, et al. · Journal of pharmaceutical sciences · 2025
  4. Comparison of supercritical fluid chromatography and reverse phase liquid chromatography for the impurity profiling of the antiretroviral drugs lamivudine/BMS-986001/efavirenz in a combination tablet
    Alexander AJ, Zhang L, Hooker TF, et al. · Journal of pharmaceutical and biomedical analysis · 2013 · 被引 20cited 20
  5. Identification, isolation, and characterization of potential degradation products in a triple combination lamivudine, zidovudine, and nevirapine tablet for oral suspension
    Aparna P, Rao SV, Thomas KM, et al. · Die Pharmazie · 2010 · 被引 2cited 2
  6. The Validation of a Simple, Robust, Stability-Indicating RP-HPLC Method for the Simultaneous Detection of Lamivudine, Tenofovir Disoproxil Fumarate, and Dolutegravir Sodium in Bulk Material and Pharmaceutical Formulations
    Omoteso OA, Milne M, Aucamp M · International journal of analytical chemistry · 2022 · 被引 3cited 3

合成与制备工艺专利Synthesis & process patents

  1. Synthesis and preparation process of lamivudine intermediate HDMS
    SHOUYING MA, JIAGEN ZHENG · 公开号 CN101830893CN101830893 · 2010
  2. AN IMPROVED PROCESS FOR THE MANUFACTURE OF LAMIVUDINE
    ROY BHAIRAB NATH, SINGH GIRIJ PAL, SHRIVASTAVA DHANANJAI, JADHAV HARISHCHANDRA SAMBHAJI, et al. · 公开号 WO2011141805WO2011141805 · 2011
  3. PROCESS FOR STEREOSELECTIVE SYNTHESIS OF LAMIVUDINE
    LI JINLIANG, LV FENG · 公开号 US2010063283US2010063283 · 2010
  4. PROCESS FOR STEREOSELECTIVE SYNTHESIS OF LAMIVUDINE
    LI JINLIANG, LV FENG · 公开号 US2011118465US2011118465 · 2011
  5. PREPARATION OF LAMIVUDINE FORM I
    COHEN BENJAMIN, WAHL CHRISTOPHER, ARROYO ITZIA Z, COTE AARON S · 公开号 WO2011100381WO2011100381 · 2011

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

拉米夫定 杂质谱研究要点Lamivudine — impurity profiling notes

下面这些是拿到 拉米夫定 的 33 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 33 impurity entries for Lamivudine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances